Evidence map›Paper›PMID 37403703›Full record

ArticleJournal of medical virology2023

Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.

Glenn Hogan, Benjamin Y Winer, James Ahodantin, Julie Sellau, Tiffany Huang, Florian Douam, Masaya Funaki, Luis Chiriboga, Lishan Su, Alexander Ploss

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Glenn HoganLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Benjamin Y WinerLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
James AhodantinDivision of Virology, Pathogenesis and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Julie SellauLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Tiffany HuangLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Florian DouamLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.
Masaya FunakiDivision of Virology, Pathogenesis and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Luis ChiribogaDepartment of Pathology, New York University Medical Center, New York, New York, USA.
Lishan SuDivision of Virology, Pathogenesis and Cancer, Institute of Human Virology, Departments of Pharmacology, Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Alexander PlossLewis Thomas Laboratory, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.ORCID 0000-0001-9322-7252
Princeton University · USUniversity of North Carolina at Chapel Hill · USColumbia University Irving Medical Center · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Tracie Saunders · 1997 to 2026
$94.5M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007388 · NIGMS · PRINCETON UNIVERSITY · PI CRISTEA, ILEANA M. · 1985 to 2022
$27.4M
Rational design and efficacy testing of vaccines against HCVR01AI168048 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Alexander Andrianov, Thomas R Fuerst · 2022 to 2026
$7.1M
Modeling immune impairments and pathogenesis in novel humanized mice for HBV-HIV co-infectionR01AI138797 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PLOSS, ALEXANDER, SU, LISHAN · 2018 to 2022
$3.9M
Data-Driven Mathematical and Computational Modeling of Hepatitis D Infection and Treatment ResponseR01AI146917 · NIAID · LOYOLA UNIVERSITY CHICAGO · PI DAHARI, HAREL · 2020 to 2024
$3.5M
Mechanisms of hepatitis B virus cccDNA formationR01AI153236 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER · 2020 to 2024
$2.8M
Immune Mechanisms of Elevated Liver Diseases During HIV InfectionR01DK119937 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2018 to 2022
$1.9M
Sandy Recovery Ventana Medical Systems Discovery XTS10OD018338 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHIRIBOGA, LUIS A · 2014 to 2014
$123k
NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA072720NIAID NIH HHS R01 AI138797NIAID NIH HHS R01 AI146917NIAID NIH HHS R01 AI153236NIAID NIH HHS R01 AI168048NIDDK NIH HHS R01 DK119937NIGMS NIH HHS T32 GM007388NIH HHS S10 OD018338
6 · The paper itself

Abstract

Chronic hepatitis B (CHB), caused by hepatitis B virus (HBV), remains a major medical problem. HBV has a high propensity for progressing to chronicity and can result in severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma. CHB patients frequently present with viral coinfection, including human immunodeficiency virus type (HIV) and hepatitis delta virus. About 10% of chronic HIV carriers are also persistently infected with HBV, which can result in more exacerbated liver disease. Mechanistic studies of HBV-induced immune responses and pathogenesis, which could be significantly influenced by HIV infection, have been hampered by the scarcity of immunocompetent animal models. Here, we demonstrate that humanized mice dually engrafted with components of a human immune system and a human liver supported HBV infection, which was partially controlled by human immune cells, as evidenced by lower levels of serum viremia and HBV replication intermediates in the liver. HBV infection resulted in priming and expansion of human HLA-restricted CD8+ T cells, which acquired an activated phenotype. Notably, our dually humanized mice support persistent coinfections with HBV and HIV, which opens opportunities for analyzing immune dysregulation during HBV and HIV coinfection, and preclinical testing of novel immunotherapeutics.

Indexed as

CoinfectionHepatitis BHepatitis B, ChronicHIV InfectionsAnimalsCD8-Positive T-LymphocytesFibrosisHepatitis B virusHIVHumansLiverMiceAIDSantiviral immunityHBVhepatitis B virusHIVhumanized micespecies tropism

Identifiers

PMID37403703
PMCPMC11298785
OpenAlexW4383186447

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.